1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Iran Pharmaceuticals and Healthcare Report Q1 2016

Iran Pharmaceuticals and Healthcare Report Q1 2016

  • December 2015
  • -
  • Business Monitor International
  • -
  • 95 pages

Includes 3 FREE quarterly updates

BMI View: In light of easing economic sanctions, international drugmakers - both R&D-based and genericdrug firms - will seek to gain a local presence in Iran's pharmaceutical market Import restrictions meansupply opportunities will be very problematic for generic drugmakers without a local presence The supplyof patented drugs will be easier for multinationals, although a local presence will be the ideal scenario formost drugmakers

Headline Expenditure Projections

- Pharmaceuticals: IRR6070tn (USD235bn) in 2014 to IRR6955trn (USD193bn) in 2015; +146% inlocal currency terms and -178% in US dollar terms Forecast unchanged from previous quarter
- Healthcare: IRR71191trn (USD2239bn) in 2014 to IRR81973trn (USD2277bn) in 2015; +151% inlocal currency terms and +17% in US dollar terms Forecast slightly upgraded from previous quarter

Table Of Contents

Iran Pharmaceuticals and Healthcare Report Q1 2016
BMI Industry View 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Iran 2011-2019) 14
Healthcare Market Forecast 15
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Iran 2011-2019) 17
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Iran 2011-2019) 18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Iran 2011-2019) 19
Prescription Drug Market Forecast 20
Patented Drug Market Forecast 21
Generic Drug Market Forecast 22
OTC Market Forecast 23
Pharmaceutical Trade Forecast 24
Table: Pharmaceutical Trade Data And Forecasts (Iran 2013-2019) 27
Table: Pharmaceutical Trade Data And Forecasts local currency (Iran 2013-2019) 27
Key Risks To BMI's Forecast Scenario 28
Industry Risk/Reward Index 29
Middle East and Africa Risk/Reward Index - Q1 2016 29
Iran Risk/Reward Index 37
Rewards 37
Risks 38
Regulatory Review 39
Intellectual Property Regime 41
Counterfeit Medicines 42
Pricing And Reimbursement 43
Market Overview 45
Healthcare Sector 46
Table: Healthcare Resources (Iran 2009-2014) 48
Table: Healthcare Personnel (Iran 2009-2014) 49
Table: Healthcare Activity (Iran 2009-2014) 49
Healthcare Insurance 49
International Healthcare Collaboration 51
Traditional Herbal Remedies 51
Research and Development 52
Biotechnology 53
Clinical Trials 56
Epidemiology 56
Competitive Landscape 60
Pharmaceutical Sector 60
Generic Drugmakers 63
Table: Leading Drug Manufacturers, Iranian Year To March 20, 2009 63
Pharmaceutical Distribution 66
Table: Leading Distributors, Iranian Year To March 20 2008 67
Pharmaceutical Retail Sector 68
Table: Tehran Stock Exchange - Listed Pharmaceutical Companies As Of November 2015 68
Table: Multinational Company Activity 69
Company Profile 71
Caspian Tamin Pharmaceutical Company 71
Darou Pakhsh 74
Exir Pharmaceuticals 77
Pars Darou 79
Zahravi Pharmaceutical Company 81
Demographic Forecast 84
Table: Population Headline Indicators (Iran 1990-2025) 85
Table: Key Population Ratios (Iran 1990-2025) 85
Table: Urban/Rural Population and Life Expectancy (Iran 1990-2025) 86
Table: Population By Age Group (Iran 1990-2025) 86
Table: Population By Age Group % (Iran 1990-2025) 87
Glossary 89
Methodology 91
Pharmaceutical Expenditure Forecast Model 91
Healthcare Expenditure Forecast Model 91
Notes On Methodology 92
Risk/Reward Index Methodology 93
Index Overview 94
Table: Pharmaceutical Risk/Reward Index Indicators 94
Indicator Weightings 95

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025 Summary Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregula ...

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025 Summary Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.